Breaking News Instant updates and real-time market news.

ATRC

AtriCure

$17.96

0.01 (0.06%)

18:16
12/10/17
12/10
18:16
12/10/17
18:16

Piper Jaffray remains bullish on AtriCure, sees potential acceleration in 2020

Piper Jaffray analyst Matt O'Brien notes that he hosted investor meeting with AtriCure's CFO Andy Wade. Looking longer-term, the analyst believes the results of the Converge trial and a sub-x Clip might result in accelerating growth starting in 2020, which he believes would push shares much higher. Consequently, O'Brien encourages investors to start or build positions in this "compelling franchise." He reiterates an Overweight rating and $24 price target on the shares.

  • 12

    Dec

ATRC AtriCure
$17.96

0.01 (0.06%)

03/06/17
BTIG
03/06/17
DOWNGRADE
BTIG
Neutral
AtriCure downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded AtriCure to Neutral citing the recent rally in shares, continued lack of clarity around the DEEP trial, and potentially slower enrollment than expected in CONVERGE.
05/30/17
PIPR
05/30/17
INITIATION
Target $26
PIPR
Overweight
AtriCure assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien assumed coverage of AtriCure with an Overweight rating and $26 price target. The company offers a "unique" way to play some fast growth areas within the large coronary market, the analyst contends.
07/17/17
ADAM
07/17/17
NO CHANGE
ADAM
M&A in med-tech space will accelerate, says Canaccord
Canaccord analyst Jason Mills remains cautious in the med-tech space but believes M&A will continue to be a major theme. He noted the sector is trading at peak levels and recommends trading around core positions and looking for pullbacks to average down in favorite names. He said the most likely takeout names, in this order, are, Nevro (NVRO), AtriCure (ATRC), NxStage Medical (NXTM), iRhythm (IRTC), and Penumbra (PEN).
11/02/17
PIPR
11/02/17
NO CHANGE
Target $24
PIPR
Overweight
AtriCure weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends using the post-earnings weakness in shares of AtriCure as a buying opportunity. The lowered sales outlook is largely the result of a spillover of deferrals from physician disruptions and fires in California, O'Brien tells investors in a post-earnings research note. The analyst views the headwinds as transitory and believes AtriCure can reaccelerate growth into 2018. He lowered his price target for the shares to $24 from $26 and maintains an Overweight rating on the name.

TODAY'S FREE FLY STORIES

09:45
07/17/18
07/17
09:45
07/17/18
09:45
General news
Housing Market Index to be reported at 10:00 »

July Housing Market Index…

09:45
07/17/18
07/17
09:45
07/17/18
09:45
General news
Breaking General news story  »

Federal Reserve Chairman…

CMCSA

Comcast

$34.98

(0.00%)

, CMCSK

Comcast

$0.00

(0.00%)

09:42
07/17/18
07/17
09:42
07/17/18
09:42
Periodicals
NBCU relaunches Craftsy as subscription-video service Bluprint, Variety reports »

NBCUniversal Cable…

CMCSA

Comcast

$34.98

(0.00%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$124.70

(0.00%)

09:42
07/17/18
07/17
09:42
07/17/18
09:42
Hot Stocks
Johnson & Johnson says 'disappointed' in Spine & Knee medical sales results »

Says Spine still an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 08

    Aug

BA

Boeing

$356.01

(0.00%)

09:41
07/17/18
07/17
09:41
07/17/18
09:41
Hot Stocks
Boeing, Xiamen Airlines announce optimized maintenance program deal »

Boeing and Xiamen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SNA

Snap-On

$163.93

(0.00%)

09:41
07/17/18
07/17
09:41
07/17/18
09:41
Recommendations
Snap-On analyst commentary  »

Snap-On checks point to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 16

    Aug

VEON

Veon

$3.05

(0.00%)

, HFC

HollyFrontier

$68.91

(0.00%)

09:40
07/17/18
07/17
09:40
07/17/18
09:40
Options
Unusually active option classes on open July 17th »

Unusual total active…

VEON

Veon

$3.05

(0.00%)

HFC

HollyFrontier

$68.91

(0.00%)

DUST

Direxion Daily Gold Miners Bear 3X ETF

$25.49

(0.00%)

UNH

UnitedHealth

$257.03

(0.00%)

JNJ

Johnson & Johnson

$124.70

(0.00%)

CZR

Caesars

$11.63

(0.00%)

GS

Goldman Sachs

$231.01

(0.00%)

MCD

McDonald's

$158.76

(0.00%)

ATVI

Activision Blizzard

$80.23

(0.00%)

GDX

Market Vector Gold Miners

$21.88

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 08

    Aug

NFLX

Netflix

$400.24

4.32 (1.09%)

09:38
07/17/18
07/17
09:38
07/17/18
09:38
Recommendations
Netflix analyst commentary  »

Netflix Q2 weakness is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$194.01

-2 (-1.02%)

09:36
07/17/18
07/17
09:36
07/17/18
09:36
Initiation
Wex initiated  »

Wex initiated with a Peer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$231.01

4.71 (2.08%)

09:36
07/17/18
07/17
09:36
07/17/18
09:36
Periodicals
Lloyd Blankfein writes farewell memo to Goldman Sachs team, NY Times reports »

Goldman Sachs CEO LLoyd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVRO

Nevro

$58.79

1.04 (1.80%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Recommendations
Nevro analyst commentary  »

Nevro price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

FLT

FleetCor

$216.11

-4.06 (-1.84%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
FleetCor initiated  »

FleetCor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$66.95

-0.06 (-0.09%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
Square initiated  »

Square initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 15

    Aug

  • 16

    Aug

FIS

FIS

$107.72

-0.45 (-0.42%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
FIS initiated  »

FIS initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

09:35
07/17/18
07/17
09:35
07/17/18
09:35
General news
Treasury Action: yields traded mixed-to-lower with stocks »

Treasury Action: yields…

EPAM

Epam Systems

$132.28

-1.3 (-0.97%)

09:34
07/17/18
07/17
09:34
07/17/18
09:34
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 15

    Aug

  • 16

    Aug

PAYX

Paychex

$69.99

-0.57 (-0.81%)

09:34
07/17/18
07/17
09:34
07/17/18
09:34
Initiation
Paychex initiated  »

Paychex initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FISV

Fiserv

09:34
07/17/18
07/17
09:34
07/17/18
09:34
Initiation
Fiserv initiated  »

Fiserv initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

CLGX

CoreLogic

$53.31

0.04 (0.08%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
CoreLogic initiated  »

CoreLogic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
Alliance Data initiated  »

Alliance Data initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

WU

Western Union

$20.27

-0.09 (-0.44%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
Western Union initiated  »

Western Union initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$137.13

-0.19 (-0.14%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
ADP initiated  »

ADP initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

DXC

DXC Technology

$85.74

-0.41 (-0.48%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Initiation
DXC Technology initiated  »

DXC Technology initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$167.63

-0.48 (-0.29%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Initiation
Accenture initiated  »

Accenture initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$63.96

-0.74 (-1.14%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Technical Analysis
Technical Earnings Preview: CSX may have double-topped before news »

On the 1-year, daily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.